SLC40A1^(+)macrophages contribute to the immunosuppressive tumor microenvironment in EGFR-mutated lung cancer  

SLC40A1^(+)巨噬细胞在EGFR突变肺癌免疫抑制性肿瘤微环境中的作用

作　　者：Xinyu Song Zongjuan Li Xuanhe Wang He Du Yijun Jia Shen Chen Anwen Xiong Wei Li Xuefei Li Lei Cheng Chao Zhao Lei Wang Guanghui Gao Xiaoxia Chen Chunyan Wu Zhikai Zhao Shengxiang Ren Caicun Zhou Fengying Wu 宋心宇;李宗娟;王煊赫;杜贺;贾怡君;陈申;熊安稳;李玮;李雪飞;程磊;赵超;王雷;高广辉;陈晓霞;武春燕;赵志凯;任胜祥;周彩存;吴凤英

机构地区：[1]Department of Medical Oncology,Qilu Hospital of Shandong University,Jinan 250012,China [2]Department of Medical Oncology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China [3]Department of Medical Oncology,Shanghai East Hospital,School of Medicine,Tongji University,Shanghai 200120,China [4]Department of Lung Cancer and Immunology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China [5]Department of Pathology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China

出　　处：《Science Bulletin》2025年第1期47-50,共4页科学通报(英文版)

基　　金：supported by the China Postdoctoral Science Foundation(2023M742119);the National Natural Science Foundation of China(82403395,82373319,and 82102766);the Natural Science Foundation of Shandong Province(ZR2024QH219);the National Key Clinical Program on Oncology;the Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project(23Y11908600)。

摘　　要：Patients with non-small cell lung cancer(NSCLC)harboring epidermal growth factor receptor(EGFR)mutations show a notable response to tyrosine kinase inhibitor(TKI)treatment.However,almost all patients eventually develop resistance[1].Given the limited post-resistance treatment options,identifying effective solutions for this sizable group has become a pressing clinical concern.The emergence of immunotherapy has marked a significant breakthrough for patients with NSCLC without driver gene mutations.However,its efficacy remains a subject of debate on the carriers of EGFR mutation.While preclinical studies have hinted at the potential benefits of immunotherapy for patients with EGFR mutations,early clinical investigations have painted a less optimistic picture[2,3].

关 键 词：LUNG cancer eventually 

分 类 号：R734.2[医药卫生—肿瘤]